Wegovy Pill Maintains GLP-1 Oral Market Lead as Competitive Pressure Builds
Novo Nordisk’s weight-loss tablet, known as the Wegovy pill, is still dominating the market for oral GLP-1 drugs. In the week ending May 22, doctors wrote around 146,000 prescriptions for it. This shows how incredibly popular the pill has become in a very short amount of time. Nevertheless, weekly growth has slowed down to about 2 percent. This suggests that the market is finally starting to make room for new rivals, and the initial massive rush of patients might be stabilizing. In light of this, industry experts are watching closely to see if Novo Nordisk can keep up this momentum or if the peak is already in sight.
Even with this slower growth, the Wegovy pill’s early success is hard to deny. To be precise, when you look at Eli Lilly’s injectable drug Zepbound at the exact same point in its launch, the Wegovy pill is moving about 2.4 times more volume. Building on this, the numbers show just how much patients want a simple pill instead of a needle. Taking a pill every morning fits much better into a normal daily routine than giving yourself a weekly shot. Along with this, doctors are already very used to prescribing semaglutide for weight loss, so they do not hesitate to recommend it to new patients.
Meanwhile, Eli Lilly officially jumped into the oral market this past April with its own weight-loss tablet called Foundayo. By its sixth week on store shelves, Foundayo brought in roughly 16,000 prescriptions. This is a solid start for a brand-new drug, but it is still a small fraction of what Wegovy is doing. Notably, Lilly hasn’t even started its main advertising campaign for the pill yet. Furthermore, many insurance companies are still deciding whether they will cover the medication. As a result, these numbers could shoot up quickly once their marketing team gets to work and insurance approvals open up for more patients.
Having weight-loss options in a pill format is a massive step forward for medicine. Popular shots like Ozempic, Wegovy, and Mounjaro originally proved how well these types of drugs work to curb appetite and shed pounds. For a long time, making a pill version was tough because the body couldn’t absorb the drug well through the stomach. The stomach acid would often break it down before it could do any good. Consequently, this new generation of tablets is a huge deal for anyone who hates needles, suffers from injection anxiety, or simply cannot use regular shots due to storage and travel issues.
In the coming months, insurance coverage and health regulations will decide who wins this market. Things like whether a specific insurance plan covers the drug, how much a patient has to pay out of pocket, and new FDA updates will heavily sway what doctors choose to prescribe. Therefore, while these early sales numbers show us who is winning right now, they don’t tell the whole story of how this pharmaceutical battle will end. Accordingly, as both companies ramp up production to avoid supply shortages, the real competition is just heating up.
